Related Experiment Video
Updated: May 7, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
Induction of sarcomas by mutant IDH2
Chao Lu1, Sriram Venneti, Altuna Akalin
1Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA;
Abstract:
More than 50% of patients with chondrosarcomas exhibit gain-of-function mutations in either isocitrate dehydrogenase 1 (IDH1) or IDH2. In this study, we performed genome-wide CpG methylation sequencing of chondrosarcoma biopsies and found that IDH mutations were associated with DNA hypermethylation at CpG islands but not other genomic regions. Regions of CpG island hypermethylation were enriched for genes implicated in stem cell maintenance/differentiation and lineage specification. In murine 10T1/2 mesenchymal progenitor cells, expression of mutant IDH2 led to DNA hypermethylation and an impairment in differentiation that could be reversed by treatment with DNA-hypomethylating agents. Introduction of mutant IDH2 also induced loss of contact inhibition and generated undifferentiated sarcomas in vivo. The oncogenic potential of mutant IDH2 correlated with the ability to produce 2-hydroxyglutarate. Together, these data demonstrate that neomorphic IDH2 mutations can be oncogenic in mesenchymal cells.
Insights
Gain-of-function mutations in isocitrate dehydrogenase (IDH) drive chondrosarcoma by causing DNA hypermethylation. This epigenetic alteration impairs cell differentiation and promotes tumor formation, highlighting IDH mutations as key oncogenic drivers.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Over 50% of chondrosarcoma patients have mutations in isocitrate dehydrogenase 1 (IDH1) or IDH2.
- IDH mutations are known to affect cellular metabolism.
Purpose of the Study:
- To investigate the epigenetic consequences of IDH mutations in chondrosarcoma.
- To determine the oncogenic potential of mutant IDH2 in mesenchymal cells.
Main Methods:
- Genome-wide CpG methylation sequencing of chondrosarcoma biopsies.
- Expression of mutant IDH2 in murine mesenchymal progenitor cells.
- In vivo tumor formation studies.
- Measurement of 2-hydroxyglutarate production.
Main Results:
- IDH mutations were strongly associated with DNA hypermethylation specifically at CpG islands.
- Hypermethylated regions were enriched for genes involved in stem cell maintenance and lineage specification.
- Mutant IDH2 expression in cells caused DNA hypermethylation, impaired differentiation, and loss of contact inhibition.
- Mutant IDH2 induced undifferentiated sarcomas in vivo, with oncogenic potential correlating to 2-hydroxyglutarate production.
Conclusions:
- Neomorphic IDH2 mutations are oncogenic in mesenchymal cells.
- IDH-driven DNA hypermethylation contributes to chondrosarcoma development.
- Targeting IDH mutations or their downstream effects may offer therapeutic strategies.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic cells are...
Abnormal Proliferation
Cancers Originate from Somatic Mutations in a Single Cell
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

